BioSpace News Archive

Lannett Company, Inc. announced that it has received written notice from the NYSE dated March 2, 2022, notifying the company that it is not in compliance with the continued listing standards set forth in Section 802.01B of the NYSE Listed Company Manual because its average market capitalization has been less than $50 million over a consecutive 30 trading-day period, and at the same time its last reported stockholders’ equity was below $50 million.

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2021, shared recent operational progress, and provided a corporate update.

UroGen Pharma Ltd. a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, announced the grants of inducement restricted stock units to 12 new employees in connection with their employment with UroGen.

SCYNEXIS, Inc., a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, announced grants of stock options and Restricted Stock Units to three new employees.

Globus Medical, Inc., a leading musculoskeletal solutions company, announced that its Board of Directors has expanded the Company’s share repurchase program by authorizing the repurchase of an additional $200 million of the Company’s common stock.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on March 1, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 9,375 shares of Puma common stock to one new non-executive employee.

Lannett Company, Inc. announced that the company will participate in a fireside chat at the 34th Annual ROTH Conference on March 14, 2022 at 12:30 p.m. PT at The Ritz Carlton, in Laguna Niguel, California.

Bristol Myers Squibb announced that the U.S. Food and Drug Administration approved Opdivo® 360 mg in combination with platinum-doublet chemotherapy every three weeks for three cycles for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting.

The global home healthcare market is expected to grow at a remarkable CAGR 14.2% over the forecast period 2021 to 2027, according to new study by Precedence Research.

Researchers from the Minds Matter Concussion Program and the Center for Violence Prevention at Children’s Hospital of Philadelphia have identified important differences in the initial evaluation and outcomes between patients who suffered a concussion as the result of assault compared with those who suffered a concussion sustained during sports.